Recombinant Factor Ⅷ for Treatment of Patients with Hemophilia A in China
- VernacularTitle:重组人凝血因子Ⅷ在中国人血友病A患者中的安全性和有效性探讨
- Author:
Baosheng LI
;
Haihong YAN
- Publication Type:Journal Article
- Keywords:
Recombinant factorⅧ;
Hemophilia A;
FactorⅧ activity
- From:
China Pharmacy
2005;0(17):-
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the safety and efficacy of second-generation recombinant factor Ⅷ (Kogenate FS) for treatment of patients with hemophilia A in China. METHODS: 16 patients with hemophilia A were treated with Kogenate FS. The factor Ⅷ antibodies and factorⅧ activities (FⅧ∶ C) were determined before and after the treatment. RESULTS: In the treatment of Kogenate FS for 16 patients with hemophilia A,15 (93.75%) recovered and 1 (6.25%) improved,and irreversible adverse drug reaction was seen in only 1 case. CONCLUSION: The second-generation recombinant factor Ⅷ product (Kogenate FS) was safe,efficacious and well-tolerated for patients with hemophilia A in China.
